No Data
Japan Regenerative Medicine Market Trends and Forecasts to 2035 Featuring Astellas Pharma, Fujifilm, JCR Pharmaceuticals, Sumitomo Pharma, Takeda, and Terumo
Sumitomo Pharma Profit Surges on Higher Revenue and Cost Controls
Sumitomo Pharma Issues Cautious FY2025 Results Conference Materials
Sumitomo Pharma: 2025 Fiscal Year (Fiscal Year Ending March 2026) Financial Results Presentation Materials
Sumitomo Pharma: Supplementary Materials for the 2025 Fiscal Year (Fiscal Year Ending March 2026) Financial Results (IFRS)
Sumitomo Pharma: Interim Financial Results for the Fiscal Year Ending March 2026 [IFRS] (Consolidated)
Cui Nyonya Kueh :
72763913 : hello now put time?